Atlas' next chapter

After separating from the tech group, Atlas Venture's healthcare team plans to stick to the early stage investing strategy the firm says has provided returns in the top quartile of life science VCs.

For the last six years or so, that strategy has revolved around giving small amounts of highly tranched seed funding to start-ups - often formed around ideas plucked from academia - and telling them to "prove" they are viable. The firm employs a range of investment models, from building companies around big ideas to an asset-centric approach...